CRX with neutralizing properties constitutes the 3 rd cornerstone of Bionor’s HIV program
Oslo, February 7, 2019 The recent Proof of Mechanism shown for CRX demonstrates the dynamic properties of this product obstructing both of the well-known virus entry mechanisms CCR5 and CXCR4…
Bionor’s 3rd vaccine candidate, CRX, Proof of Mechanism established
Oslo, January 23, 2019. Bionor is pleased to announce that Proof of Mechanism is established for our 3rd vaccine candidate, CRX. This product aims to prevent binding between gp120 V3…
Bionor has acquired its 3rd HIV vaccine candidate, CRX.
Oslo, January 10, 2019 The acquisition is in the form of an exchange of patents and rights between Bionor and Immunor AS. During Bionor’s equity raise in December 2017, Bionor…
Change of name to Bionor Holding AS
Oslo, January 29.1.2018 In an Extraordinary General Meeting today, the shareholders unanimously adopted to change the name of the company from Bionor Pharma AS to Bionor Holding AS. The change…
Birger Sørensen and his team closed the purchase and funding of Bionor today
Oslo, December 8, 2017 Bionor was purchased by the founder of Bionor AS, Birger Sørensen and his team, on September 28, 2017 with financial closing as of today. With the…
Strategic partnership between Smerud Medical Research International and Bionor
Oslo, November 24, 2017 Bionor is proud to announce that the company on November 24 entered into a strategic partnership with Smerud Medical Research International (SMRI). This partnership will focus…
New strategy for combining Vacc-4x and Vacc-C5 with a defined path that can lead to a regulatory approval and commercialization
Bionor’s strategy is to develop the combination of its two proprietary therapeutic HIV vaccines Vacc-4x and Vacc-C5 and seek advice on and adapt its regulatory path so that a marketing…
The founder of Bionor, Birger Sørensen, and his team has repurchased the company
Oslo, September 28, 2017 Bionor was purchased by the founder of Bionor AS, Birger Sørensen and his team, on September 28, 2017. The new owners/management will focus on implementing a…
Vacc-C5 phase I/II clinical study published in BMC infectious diseases
The Vacc-C5 clinical trial is included as part of the doctor thesis of Kristin Brekke at Oslo University Hospital Background Levels of non-neutralising antibodies (AB) to the C5 domain of…
Bionor Pharma presents REDUC clinical trial results as a poster at GLOBVAC
The Research Council of Norway’s 10th Conference on Global Health and Vaccination Research where Bionor presents the Vacc-4x REDUC clinical trial results. The REDUC clinical trial was partly funded by…